Neoplasms by Site Completed Phase 2 Trials for Trabectedin (DB05109)

Back to Neoplasms by Site
IndicationStatusPhase
DBCOND0030096 (Neoplasms by Site)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00050427A Study of ET-743 (Trabectedin) in Patients With Advanced Breast CancerTreatment
NCT00050414A Study of Trabectedin in Patients With Advanced Ovarian CancerTreatment